Suppliers and packagers for KUVAN

KUVAN

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Biomarin Pharm	KUVAN	sapropterin dihydrochloride	POWDER;ORAL	205065	NDA	BioMarin Pharmaceutical Inc.	68135-301-22	30 PACKET in 1 CARTON (68135-301-22) / 1 POWDER, FOR SOLUTION in 1 PACKET (68135-301-11)	2014-02-21
Biomarin Pharm	KUVAN	sapropterin dihydrochloride	POWDER;ORAL	205065	NDA	BioMarin Pharmaceutical Inc.	68135-482-11	30 PACKET in 1 CARTON (68135-482-11) / 1 POWDER, FOR SOLUTION in 1 PACKET (68135-482-10)	2015-05-27
Biomarin Pharm	KUVAN	sapropterin dihydrochloride	TABLET;ORAL	022181	NDA	BioMarin Pharmaceutical Inc.	68135-300-02	120 TABLET in 1 BOTTLE (68135-300-02)	2007-12-14

Kuvan (Sapropterin) Suppliers: Who Manufactures and Supplies the Drug, API, and Key Components for US and Global Markets

Last updated: May 28, 2026

Kuvan (sapropterin; tetrahydrobiopterin, BH4 replacement) supply is handled through branded-product distribution in the US and through generic and API supply chains globally, with manufacturing/labeling responsibilities tied to the commercial product holder. The drug’s supply does not map cleanly to a single “API-only” supplier in public disclosures; it is typically sourced through finished-dose manufacturers and licensed distributors rather than openly published “component lists” for buyers.

Who supplies Kuvan in the US market?

Primary distribution in the US is through the labeled drug’s commercial supply chain (manufacturer plus wholesale/distribution network), not through a publicly maintained “supplier roster” for procurement. For “suppliers,” the practical buyer target is the US-labeler/manufacturer of record for Kuvan tablets and the authorized wholesalers/distributors that carry the product for channels (hospital, specialty pharmacy, retail).

What entities typically appear in Kuvan’s supply chain?

In US drug procurement, the following supplier roles matter:

• Finished-dose manufacturer of record (manufactures tablets under the NDA/BLA manufacturing license for the product labeled as Kuvan)
• NDA holder/commercial sponsor (owns the commercial product and coordinates supply)
• Authorized wholesalers/distributors (sell into retail and institutional channels)
• GPO and specialty channel providers (indirect purchasing routes for health systems)

How procurement teams usually validate “the supplier” for Kuvan

• Confirm the labeler name and manufacturer of record on the NDC packaging
• Match the NDC to the FDA label and product listing
• Track lot-level manufacturing site (where applicable) through CoA and packaging traceability
• Validate cold-chain or stability handling requirements (Kuvan is typically stored at controlled room temperature ranges, but lot-specific handling still matters)

What manufacturing companies make Kuvan tablets?

Kuvan is produced by finished-dose manufacturers under the product’s NDA manufacturing arrangements. Public supplier identification depends on what you treat as “supplier”: company making the tablets vs. company supplying the API vs. company distributing the branded product.

What to check to identify the finished-dose manufacturer

• Package insert labeling: “Manufactured for/Manufactured by” lines
• FDA label (current label) and NDC directory: manufacturer/labeler text
• CoA and packaging: manufacturing site per lot

Why API suppliers are harder to pin down publicly

• API suppliers change due to qualification and ongoing supply risk management.
• Public sources often report the finished-dose manufacturer, not every API supplier, unless the API supplier is disclosed in inspections, consent decrees, or certain regulatory filings.

Which companies supply sapropterin (BH4) API for Kuvan?

Sapropterin API supply is part of a specialty chemical and pharma-grade API supply chain and is not consistently disclosed as a public “named vendor list” for Kuvan. In procurement practice, buyers identify API sources through:

• audit and qualification documentation,
• supplier master files,
• regulatory dossiers for the specific manufacturing site,
• and lot-level CoA supplier stamps.

How an API procurement team typically characterizes “sapropterin API supply”

• API vendor identity at time of qualification
• DMF status (where relevant) and manufacturing site controls
• GMP compliance history for the API site
• change-control history (site transfers, re-qualification triggers)

Are there generic Kuvan alternatives that change the supplier landscape?

Yes. The branded-product supply chain can be complemented by generic sapropterin products where available, which changes the set of finished-dose manufacturers in the market.

What to evaluate when mapping competitors as “suppliers”

• Generic NDC manufacturer(s)
• approval date and launch status
• whether the generic is tablet strengths and labeling that match Kuvan use
• supply continuity by finished-dose site

What regulatory documents reveal Kuvan supplier/manufacturer details?

The key regulatory artifacts for supplier identification are FDA label/NDC information and any relevant inspection or enforcement records tied to manufacturing sites.

Primary references for identifying supplier and manufacturing site

• FDA drug label for Kuvan tablets (current prescribing information)
• FDA NDC directory (labeler/manufacturer of record)
• FDA Orange Book entry (listed patents, not suppliers, but helps tie product to NDA sponsor and related manufacturing)
• FDA enforcement/inspection databases for manufacturing sites implicated in compliance actions

How do Kuvan supply and distribution partners affect availability?

Specialty drugs like Kuvan frequently rely on:

• specialty pharmacy distribution
• hub services (where the sponsor supports enrollment and refill logistics)
• limited distribution agreements that constrain who can sell into specific channels

What buyers should operationalize

• multi-channel procurement strategy (specialty pharmacy vs. wholesaler)
• alternate NDC sourcing in cases of lot-specific shortages (where product interchangeability is allowed)

Patent and exclusivity status can indirectly affect supply

Even though the question is about “suppliers,” Kuvan’s competitive landscape and exclusivity have a supply impact through market structure.

What to check

• Orange Book listing for Kuvan under its NDA
• date of exclusivity-driven barriers for generics
• any ongoing patent litigation that can affect launch timing for alternatives

Key Takeaways

• Kuvan “suppliers” in procurement terms map primarily to the finished-dose manufacturer of record and authorized distributors, not to a stable public list of API vendors.
• The most reliable way to identify the supplier for a purchase order is through NDC packaging labeler/manufacturer of record, then lot-level CoA traceability to the manufacturing site.
• API supplier identification for sapropterin is typically handled via qualification and regulatory dossier linkage, not via a public “vendor list” that stays current.
• If you need market breadth, add generic sapropterin products to the supplier map, because they expand the number of finished-dose manufacturing sites supplying the drug category.

FAQs

1) How do I identify the manufacturer of record for Kuvan using the NDC?
Use the Kuvan NDC on the package and match it to the FDA label/NDC directory “manufacturer/labeler” text, then confirm lot-level manufacturing site via CoA.

2) Are sapropterin API suppliers listed publicly for Kuvan?
Not consistently. API suppliers usually show up through DMF/dossier references, qualification documents, or lot-level CoA, rather than as a stable branded-product “supplier list.”

3) Do generic sapropterin tablets use different manufacturing suppliers than Kuvan?
Yes, generics typically have their own NDA/generic product manufacturing sites, which changes the set of finished-dose suppliers in the market.

4) What documents are best for due diligence on Kuvan supply reliability?
CoA, lot traceability records, FDA label/NDC manufacturer text, and compliance history for the specific manufacturing site.

5) Can wholesaler availability change without a manufacturing change?
Yes. Channel distribution contracts, allocation decisions, and logistics can constrain availability even when manufacturing capacity exists.

References

1. FDA. Kuvan (sapropterin) prescribing information and label. U.S. Food and Drug Administration.
2. FDA. NDC Directory (Kuvan listings). U.S. Food and Drug Administration.
3. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (Kuvan entry). U.S. Food and Drug Administration.